Lymphoma, Diffuse Large B-Cell
7
2
3
3
Key Insights
Highlights
Success Rate
75% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
14.3%
1 terminated out of 7 trials
75.0%
-11.6% vs benchmark
0%
0 trials in Phase 3/4
33%
1 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 3 completed trials
Clinical Trials (7)
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
A Manualised Post-Traumatic Growth Intervention For People With Hematological Cancers In Greece
Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies
Comparison of Whole-body MRI, Circulating DNA and PET-CT in Staging, Prognosis, and Treatment Response in Patients with Diffuse Large Cell B Lymphoma
PNT2258 for Treatment of Patients With r/r DLBCL (Wolverine)
Pesticide Associated Lymphomas: Expression of Treatment Resistance Genes
Occupational Exposure to Pesticides in the Prognosis of Lymphomas